Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rekah Pharmaceutical ProdXTAE:REKA 57 Days Payable is 145.90 as of Mar. 2026, which is 8% above its 10-year median of 134.75. GuruFocus rates XTAE:REKA with a GF Score™ of 57/100 and a GF Value™ of ₪13.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Rekah Pharmaceutical Prod ranks better than 71.63% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:REKA vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Days Payable distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's Days Payable falls into.
Rekah Pharmaceutical Prod Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rekah Pharmaceutical Prod's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod (XTAE:REKA) has a Days Payable of 145.90 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rekah Pharmaceutical Prod and its competitors. This is near median its historical median of 134.75. Over the past decade, Rekah Pharmaceutical Prod's Days Payable has ranged from 104.69 to 152.51. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #263 out of 927 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Rekah Pharmaceutical Prod's Days Payable too high?
Rekah Pharmaceutical Prod's current Days Payable of 145.90 is near median its 10-year median of 134.75. Over the past 10 years, this metric has ranged from a low of 104.69 to a high of 152.51. The Drug Manufacturers industry median Days Payable is 90.38. Rekah Pharmaceutical Prod's value of 145.90 is 61.4% above this industry median. Based on the distribution chart, Rekah Pharmaceutical Prod ranks #263 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #263 out of 927 companies for Days Payable. This puts Rekah Pharmaceutical Prod in the upper half of its industry. The industry median Days Payable is 90.38. Rekah Pharmaceutical Prod's value of 145.90 is 61.4% above this benchmark. Historically, Rekah Pharmaceutical Prod's own Days Payable has ranged from 104.69 to 152.51 over the past decade. While the company's 10-year median is 134.75 vs. the industry median of 90.38, Rekah Pharmaceutical Prod has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rekah Pharmaceutical Prod's current Days Payable of 145.90 is 61.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rekah Pharmaceutical Prod and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current Days Payable is 145.90, which is near median its own 10-year median of 134.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.30 — trading 21.1% below its estimated fair value. The current Days Payable is 145.90, which is near median its 10-year median of 134.75 and 61.4% above the Drug Manufacturers industry median of 90.38. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current Days Payable is 145.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.30 is trading 21.1% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
Days Payable: 145.90 (near median its 10-year median of 134.75)
GF Value™: ₪13.05 vs. price of ₪10.30 (21.1% below fair value)
Industry Position: 61.4% above the Drug Manufacturers median (#263 of 927)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
